

Contents

Introduction and overview <i>Pier Mannuccio Mannucci, Flora Peyvandi</i>	S1
Recombinant activated factor VII: 30 years of research and innovation <i>Ulla Hedner</i>	S4
Recombinant activated factor VII in the treatment of bleeds and for the prevention of surgery-related bleeding in congenital haemophilia with inhibitors <i>Elena Santagostino, Miguel Escobar, Margareth Ozelo, Luigi Solimeno, Per Arkhammar, Hye Youn Lee, Gabriela Rosu, Paul Giangrande</i>	S9
The use of recombinant activated factor VII in patients with acquired haemophilia <i>Andreas Tiede, Kagehiro Amano, Alice Ma, Per Arkhammar, Soraya Benchikh el Fegoun, Anders Rosholm, Stephanie Seremetis, Francesco Baudo</i>	S19
Eptacog alfa activated: a recombinant product to treat rare congenital bleeding disorders <i>Giovanni Di Minno</i>	S26
Safety update on the use of recombinant activated factor VII in approved indications <i>Ellis J Neufeld, Claude Négrier, Per Arkhammar, Soraya Benchikh el Fegoun, Mette Duelund Simonsen, Anders Rosholm, Stephanie Seremetis</i>	S34

For a full and complete Guide for Authors, please go to:
<http://www.elsevier.com/locate/blre>